Primaquine Base 7.5mg Tablets are an efficient malaria treatment with a focus on Plasmodium vivax and ovale strains. They also help eradicate P. falciparum gametocytes following Chloroquine therapy. Each package, providing substantial quantity, is composed of 1000 film-coated tablets. These medications ensure enduring usability with a shelf life of 2 years. Marketed as a reliable malaria solution, they showcase precise formulation with Primaquine phosphate and Primaquine base.
The Primaquine Base 7.5mg Tabs/PAC-1000 are a leap forward in the fight against malaria, providing a comprehensive cure for infections caused by Plasmodium vivax and Plasmodium ovale. Digitalized not only to eradicate the leftover stages of the parasite housed within the liver but also to prevent further relapses, this treatment is fortified with a potent active compound - Primaquine Phosphate 13.2mg, equivalent to 7.5mg Primaquine base. This reaches beyond by also exterminating gametocytes of Plasmodium falciparum, and thereby reducing the risk of disease transmission.
In the struggle for Resistance Management, Primaquine Base 7.5mg emerges as an excellent ally, taking on the ever expanding issue of drug resistance in parasites. Each pack is loaded with 1000 film-coated tablets - a cost-effective and universally accessible provision.
Aligns with industry norms, this medication offers a reliable source for malaria treatment, with ample resources and guidelines for the treatment of both adult and pediatric patients. It also adheres to the WHO model formulary.